Jorge Magdaleno-Tapial

Jorge Magdaleno-Tapial

Auto-generated profile, based on publicly available information

Jorge Magdaleno-Tapial

Department of Dermatology, Hospital General Universitario de Valencia, Valencia, Spain

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 August 2020 in The Journal of Dermatology
Verified
Journal Article
Closed access
PDF file
ITIgnacio Torres‐Navarro
Ignacio Torres‐Navarro
ÁBÁlvaro Briz-Redón
Álvaro Briz-Redón
GBGonzalo Botella‐Casas
Gonzalo Botella‐Casas
ASAntonio Sahuquillo‐Torralba
Antonio Sahuquillo‐Torralba
ACAnaid Calle‐Andrino
Anaid Calle‐Andrino
RBRafael Botella‐Estrada
Rafael Botella‐Estrada

1 August 2019 in Journal of the American Academy of Dermatology
Verified
Journal Article
Open access
JOJosé-María Ortiz-Salvador
José-María Ortiz-Salvador
MSMartina Saneleuterio-Temporal
Martina Saneleuterio-Temporal
JMJorge Magdaleno-Tapial
Jorge Magdaleno-Tapial
MVManel Velasco-Pastor
Manel Velasco-Pastor
CPConrad Pujol-Marco
Conrad Pujol-Marco
APAmparo Pérez-Ferriols
Amparo Pérez-Ferriols
Secukinumab is a first-in-class interleukin 17A monoclonal antibody that has demonstrated an excellent safety and efficacy profile in phase 3 studies. To evaluate the effectiveness of secukinumab in daily clinical practice and to understand the clinical and epidemiologic characteristics of patients treated with secukinumab in clinical settings. In this multicenter prospective observational study, we recruited adult patients with moderate-to-severe plaque psoriasis from 12 hospitals in Spain during January-December 2016. These patients were treated with secukinumab and prospectively followed at 12-week intervals for 52 weeks. In total, 158 patients were recruited to the study. A Psoriasis Area and Severity Index (PASI) score improvement ≥75% over baseline (PASI-75) was achieved by 57%, 83.5%, 89%, and 78.5% of patients at weeks 4, 12, 24, and 52, respectively. PASI-90 was achieved in 27.8%, 62%, 64.6%, and 63.2% of patients at weeks 4, 12, 24, and 52, respectively; PASI-75 and PASI-90 responders were significantly more common among patients with a body mass index <30 kg/cm2 and patients without previous biologic therapy failures. Observational study. Time from onset of psoriasis was not evaluated. Secukinumab is a safe treatment with effectiveness rates similar to those found in its phase 3 studies. These rates endure up to a year from start of treatment.

15 November 2019 in Australasian Journal of Dermatology
Verified
Journal Article
Closed access
PDF file
JMJorge Magdaleno‐Tapial
Jorge Magdaleno‐Tapial
CVCristian Alejandro Valenzuela‐Oñate
Cristian Alejandro Valenzuela‐Oñate
JOJosé María Ortiz‐Salvador
José María Ortiz‐Salvador
ÁMÁlvaro Martínez‐Doménech
Álvaro Martínez‐Doménech
MGMarta García‐Legaz‐Martínez
Marta García‐Legaz‐Martínez
APAmparo Pérez‐Ferriols
Amparo Pérez‐Ferriols

13 September 2019 in Contact Dermatitis
Verified
Journal Article
Closed access
PDF file
JMJorge Magdaleno‐Tapial
Jorge Magdaleno‐Tapial
CVCristian Valenzuela‐Oñate
Cristian Valenzuela‐Oñate
JOJosé M. Ortiz‐Salvador
José M. Ortiz‐Salvador
MGMarta García‐Legaz‐Martínez
Marta García‐Legaz‐Martínez
ÁMÁlvaro Martínez‐Domenech
Álvaro Martínez‐Domenech
VZVioleta Zaragoza‐Ninet
Violeta Zaragoza‐Ninet

1 September 2019 in Actas Dermo-Sifiliograficas
Verified
Journal Article
Closed access
JMJ. Magdaleno-Tapial
J. Magdaleno-Tapial
RCR. Carmena-Ramón
R. Carmena-Ramón
CVC. Valenzuela-Oñate
C. Valenzuela-Oñate
JOJ.M. Ortiz-Salvador
J.M. Ortiz-Salvador
JSJ. Sabater-Abad
J. Sabater-Abad
APA. Pérez-Ferriols
A. Pérez-Ferriols

14 May 2021 in Sexually Transmitted Diseases
Verified
Journal Article
Closed access
JMJorge Magdaleno-Tapial
Jorge Magdaleno-Tapial
PHPablo Hernández-Bel
Pablo Hernández-Bel
JOJosé María Ortiz-Salvador
José María Ortiz-Salvador
CLCristina López-Martí
Cristina López-Martí
ÁMÁlvaro Martínez-Doménech
Álvaro Martínez-Doménech
APAmparo Pérez-Ferriols
Amparo Pérez-Ferriols
Herpes zoster is an acute, cutaneous viral infection caused by the reactivation of varicella-zoster virus. Genital dermatomes are involved in only up to 2% of cases and are probably underrecognized. We present a series of 7 genital herpes zoster cases diagnosed in our Unit of Sexually Transmitted Diseases. None of our patients were positive for HIV test, and only one was taking immunosuppressive medication. We recommend the use of molecular testings to confirm the diagnosis of varicella-zoster virus or herpes simplex virus infection in all cases of genital herpes–like lesions.